WAT:NYE-Waters Corporation

EQUITY | Medical Diagnostics & Research | New York Stock Exchange

Last Closing

USD 250.28

Change

+5.02 (+2.05)%

Market Cap

USD 10.92B

Volume

0.36M

Analyst Target

USD 224.54
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Waters Corp is an analytical instrument manufacturer. It designs, manufactures, sells and services liquid chromatography, ultra performance liquid chromatography & mass spectrometry instrument systems & support products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-21 )

Largest Industry Peers for Medical Diagnostics & Research

ETFs Containing WAT

IVEG iShares Emergent Food and.. 4.47 % 0.00 %

+0.08 (+0.21%)

USD 4.93M
POWA Invesco Bloomberg Pricing.. 2.17 % 0.00 %

+0.15 (+0.21%)

USD 0.20B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+0.16 (+0.21%)

USD 1.18B
FIW First Trust Water ETF 0.00 % 0.55 %

+0.14 (+0.21%)

USD 1.64B
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+0.08 (+0.21%)

USD 7.79B
PHO Invesco Water Resources E.. 0.00 % 0.60 %

+0.15 (+0.21%)

USD 2.04B
PIO Invesco Global Water ETF 0.00 % 0.75 %

-0.36 (0.21%)

USD 0.29B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

-0.79 (0.21%)

CAD 0.05B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

+0.16 (+0.21%)

CAD 0.32B
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
STNC Stance Equity ESG Large C.. 0.00 % 0.00 %

+0.11 (+0.21%)

USD 0.12B
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

-10.90 (0.21%)

USD 6.45M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

-0.21 (0.21%)

USD 6.45M

Market Performance

  Market Performance vs. Industry/Classification (Medical Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 32.67% 82% B 92% A
Dividend Return N/A N/A N/A N/A F
Total Return 32.67% 82% B 92% A
Trailing 12 Months  
Capital Gain 18.52% 41% F 90% A-
Dividend Return N/A N/A N/A N/A F
Total Return 18.52% 35% F 87% B+
Trailing 5 Years  
Capital Gain 126.01% 79% B- 94% A
Dividend Return N/A N/A N/A N/A F
Total Return 126.01% 79% B- 93% A
Average Annual (5 Year Horizon)  
Capital Gain 17.18% 65% D 90% A-
Dividend Return 17.18% 65% D 88% B+
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 13.17% 65% D 55% F
Risk Adjusted Return 130.42% 71% C- 94% A
Market Capitalization 10.92B 65% D 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.60 47% 18%
Price/Book Ratio 9.75 18% 6%
Price / Cash Flow Ratio 8.03 29% 10%
Price/Free Cash Flow Ratio 37.36 41% 12%
Management Effectiveness  
Return on Equity 31.53% 94% 91%
Return on Invested Capital 24.15% 94% 88%
Return on Assets 14.47% 94% 95%
Debt to Equity Ratio 62.75% 53% 55%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.